They peak during the first 4 to 8 weeks of treatment and during dose escalations
Through a real-world analysis of tirzepatide, we identified several significant gastrointestinal ADEs, including nausea (n = 4358, ROR 5.20, PRR 4.97, IC 2.27, EBGM 4.82), constipation (n = 1215, ROR 4.48, PRR 4.43, IC 2.11, EBGM 4.32), eructation (n = 716, ROR 43.63, PRR 43.25, IC 32.71, EBGM 5.03), dyspepsia (n = 559, ROR 5.12, PRR 5.09, IC 2.30, EBGM 4.93), flatulence (n = 380, ROR 6.00, PRR 5.98, IC 2.53, EBGM 5.76), and pancreatitis (n = 307, ROR 7.18, PRR 7.16, IC 2.77, EBGM 6.84), consistent with previous clinical studies and drug labeling
COOKBOOK Get a taste of our program with the Weight Watchers GLP-1 Success Cookbookpacked with simple recipes and a structured 7-day meal plan.
They also act on appetite centres in the brain, reducing hunger and food intake
Hall, W.T.) (John Wiley & Sons, New York, New York, 1948)